Siemens Healthineers offers new assay for heart attack diagnosis
High-sensitivity troponin plays a critical role in the timely diagnosis of AMI or heart attacks.
Siemens Healthineers has announced its high-sensitivity troponin I (TNIH)1 , a new assay designed to aid in diagnosing acute myocardial infarctions (AMI) through the quantitative measurement of cardiac troponin I in serum or plasma.
High-sensitivity troponin plays a critical role in the timely diagnosis of AMI or heart attacks. AMI can be life-threatening if not treated in time because, as blood flow to the heart is blocked, the heart muscle begins to die in as little as 30 to 60 minutes.
“With the introduction of the high-sensitivity troponin I assay, Siemens Healthineers is continuing to deliver proven technologies that address the global need to improve cardiac care with fast, reliable diagnostic options for better patient outcomes,” Franz Walt, head of Siemens Healthineers’ Laboratory Diagnostics, said.
“This new assay will provide clinicians with actionable results and the confidence to act swiftly earlier,” he added. — VNS
